Neurizon Therapeutics Limited (NUZTF)
| Market Cap | 41.91M -15.0% |
| Revenue (ttm) | 12.17M +1,043.5% |
| Net Income | -7.42M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0470 |
| Previous Close | 0.0470 |
| Day's Range | 0.0470 - 0.0470 |
| 52-Week Range | 0.0454 - 0.1197 |
| Beta | 1.31 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 24, 2026 |
About Neurizon Therapeutics
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therap... [Read more]
Financial Performance
In fiscal year 2026, Neurizon Therapeutics's revenue was 17.59 million, an increase of 1043.54% compared to the previous year's 1.54 million. Losses were -10.72 million, -35.38% less than in 2025.
Financial numbers in AUD Financial StatementsNews
HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far Anticipated topline eff...
HEALEY ALS Platform Trial Regimen I expands to 240 participants
Highlights: Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requir...
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS Approximately 160 participants with ALS will be ...
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
Highlights: FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Plat...